Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aspen

- PMLiVE

Novartis to relocate UK headquarters to London’s White City

Emerging life sciences hub has already attracted Autolus

- PMLiVE

Novartis gets EU nod for Luxturna gene therapy

Approval comes almost a year after it was secured a green light in the US

- PMLiVE

Novartis’ heart failure drug Entresto proves superior to enalapril

Results could see the drug strengthen its position in the market

- PMLiVE

Novartis culls pipeline to focus on most transformative science

Anti-infectives among areas hit by streamlining

- PMLiVE

Novartis and Pfizer to collaborate on NASH combinations

Big pharma giants target nascent multi-billion market

Pharma: in search of the sustainable ‘win win’ with the NHS

Fiona Bride on how Novartis is responding to new models of care

- PMLiVE

Novartis gains label boost for Cosentyx

Updated label allows dosing flexibility of up to 300mg

- PMLiVE

Novartis claims a rare win at ESMO for PI3K inhibitor class

Analysts predict drug could hit $1.5bn annual sales

- PMLiVE

Novartis buys cancer specialist Endocyte for $2.1bn

Acquisition includes 'universal' CAR-T platform

- PMLiVE

Novartis files for approval of MS drug in EU, US

Siponimod could achieve blockbuster status if approved, says analysts

Novartis day

Novartis cuts manufacturing jobs in Switzerland and UK

Cuts include closure of Grimsby site by 2020

- PMLiVE

NHS wins legal fight with pharma over off-label Avastin

Industry criticises judgement - fearful of 'undermining regulation' as well as big earning products

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links